Skip to content

NEOnatal Multiexposure to Medical Devices Plasticizers: Endocrine Disruption MIXture Effects and Neurodevelopmental Disorders

NEOnatal Multiexposure to Medical Devices Plasticizers: Endocrine Disruption MIXture Effects and Neurodevelopmental Disorders

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06726824
Acronym
NEOMIX WP3
Enrollment
97
Registered
2024-12-10
Start date
2024-12-31
Completion date
2025-12-31
Last updated
2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodevelopmental Disorder (Diagnosis)

Keywords

Neurodevelopmental disorder, Multiexposure, Medical devices, Plasticizers, Cocktail effects

Brief summary

The goal of this observational study is to evaluate the neurodevelopment of children from the ARMED NEO cohort through the ASQ3 score. Dose the multiexposure to medical devices plasticizers during the neonatal intensive care unit stay increases the risk of developing neurodevelopmental disorders ? Patients (their parents) will complète several questionnaires (ASQ3, environnemental survey, EPICES score) during a planned teleconsultation with the research team

Interventions

None listed

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Live patient who participated in the ARMED NEO study, included at the Clermont-Ferrand or Lille hospitals * Patient whose holders of parental authority have expressed their non-opposition to their participation in the study

Exclusion criteria

* Patient whose guardians have expressed opposition to their participation in the study * Patient with no French speaking parent * patient

Design outcomes

Primary

MeasureTime frame
ASQ3® score translated into an overall numerical score corresponding to the total of 5 dimensions of the ASQ3 test.From enrollment to the end of the teleconsultation

Countries

France

Contacts

Primary ContactLise Laclautre
promo_interne_drci@chu-clermontferrand.fr0473754963

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026